Organon Makes Deal With Huya For Access To Chinese Drugs
This article was originally published in PharmAsia News
Executive Summary
Organon has signed a collaborative deal with Huya Bioscience, a San Diego-based company that promises to link the Dutch drug maker with the owners of new compounds being developed in China
You may also be interested in...
Schering-Plough Teams Up With Huya To Identify Novel Compounds In China
Schering-Plough susbsidiary Organon and Huya Bioscience International unveiled an agreement Dec. 15 under which Huya will identify and present to Organon drug candidate compounds originating in China for specific therapeutic areas
Schering-Plough Teams Up With Huya To Identify Novel Compounds In China
Schering-Plough susbsidiary Organon and Huya Bioscience International unveiled an agreement Dec. 15 under which Huya will identify and present to Organon drug candidate compounds originating in China for specific therapeutic areas
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.